SCHEMBL26107366

SCHEMBL26107366

Cc1cc(Cl)nc(NC2CCC2)c1[N+](=O)[O-]

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.52
MEN1 O00255 6/20 0.52
GABBR2 O75899 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
GABBR1 Q9UBS5 1/20 0.52
ATM Q13315 3/20 0.43
BLM P54132 2/20 0.43
LMNA P02545 2/20 0.43
MAPT P10636 2/20 0.43
GSK3A P49840 1/20 0.43
GSK3B P49841 1/20 0.43
CDK5 Q00535 1/20 0.43
CDK5R1 Q15078 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CRHBP P24387 1/20 0.43
CRHR2 Q13324 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25366543 0.94 KMT2A (0.48) KMT2AMEN1GABBR2CYP1A2CYP2C9
SCHEMBL26107588 0.85 KMT2A (0.39) KMT2AMEN1GABBR2CYP1A2CYP2C9
SCHEMBL14768721 0.82 KMT2A (0.53) KMT2AMEN1GABBR2CYP1A2CYP2C9
SCHEMBL14768732 0.80 KMT2A (0.51) KMT2AMEN1GABBR2CYP1A2CYP2C9
SCHEMBL30557558 0.78 MAPT (0.49) KMT2AMEN1CYP1A2CYP2C19TDP1
SCHEMBL16244909 0.78 MAPT (0.49) KMT2AMEN1CYP1A2CYP2C19TDP1
SCHEMBL16972784 0.77 PTGER4 (0.45) CYP2C9GSK3AGSK3BCDK5ALDH1A1
SCHEMBL26111515 0.76 PDE10A (0.40) KMT2AMEN1LMNAMAPTALDH1A1
SCHEMBL12064866 0.75 KMT2A (0.58) KMT2AMEN1GABBR2CYP1A2CYP2C9
SCHEMBL16714570 0.74 KMT2A (0.54) KMT2AMEN1GABBR2CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214991-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS 2025-07-03 US disclosed
CN-119585252-A Bicyclic heteroaryl containing compounds as IKZF2 degrading agents 翁科皮亚治疗公司和SK生命科学实验室 2025-03-07 CN disclosed
EP-4499629-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) 2025-02-05 EP disclosed
WO-2023183919-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS ONCOPIA THERAPEUTICS, INC. D/B/A PROTEOVANT THERAPEUTICS, INC. (US) 2023-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214991-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS IKZF1, IKZF2, IKZF3 KMT2A 315/4885MEN1 4258/4885GABBR2 1449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.